Company Overview - ResMed is a $37 billion company that positions itself as a "36-year-old startup" in the sleep and breathing health sector [1] - The company is the leading provider in over 140 countries, holding a market share of 50–60% in sleep apnea devices, including CPAP machines and masks [1] Investment Perspective - The company is focused on identifying undervalued stocks with a favorable risk-reward profile, emphasizing limited risks and potential for decent to high upside [1] - The belief is that the best investment ideas are often the simplest, with a contrarian approach being favored [1]

It's been a tumultuous year for U.S. stock markets. Investors have had their nerves rattled twice this year by government-related events—President Trump's Liberation Day tariffs in the spring, followed by the longest U.S. government shutdown in history this fall. That's on top of an economy already hit hard by inflation and declining consumer confidence. Yet despite this, there have still been several high-profile and successful initial public offerings throughout the year—especially in the AI and fintech s ...

Company Overview - Medline is a medical supply company that manufactures and distributes products such as masks, gowns, and lab kits [3] - The company was taken private in 2021 by a consortium of private equity firms, including Blackstone, Carlyle, and Hellman & Friedman, marking the largest leveraged buyout (LBO) post-financial crisis [3][4] IPO Details - The IPO is expected to price tonight and could be one of the largest debuts in the public markets this year, potentially valued at $55 billion, which is over $20 billion higher than the acquisition price by its sponsors [1][4] - The IPO guidance suggests pricing toward the high end of the range, indicating strong investor interest [2] Business Performance - Medline has demonstrated a resilient business model, with net sales growing each year since its inception in the 1960s at a compound annual growth rate (CAGR) of 18% [4] - The company is expected to benefit from secular tailwinds such as an aging population and the consolidation of healthcare providers [5] Growth Strategy - Medline's growth strategy includes acquiring several companies and continuing this trend to enhance its market position [5] - The concentration within Medline's business and its customer base is viewed as both a potential advantage and a risk factor [6] Market Context - The IPO is seen as a critical test for the IPO market, which has a healthy backlog of deals for 2026, and for the private equity industry, which has faced challenges in finding exits for portfolio companies [4]

Core Insights - Figs (FIGS) is valued at $1.33 billion and operates as a direct-to-consumer healthcare apparel and lifestyle brand, offering a range of products including scrubs, lab coats, activewear, and masks [1] - The stock has shown strong technical momentum, reaching a two-year high of $8.24 on October 22, and has gained 30% over the past year [4][3] Company Overview - Figs designs and sells healthcare apparel and non-scrub offerings, including sports bras, performance leggings, and loungewear, primarily through its website and mobile app [1] - The company has a 100% "Buy" technical rating from Barchart, indicating strong market confidence [4][5] Stock Performance - Since the Trend Seeker "Buy" signal was issued on October 15, the stock has appreciated by 5.28% [2] - Figs has achieved 9 new highs and a 17.25% gain in the last month, with a current trading price of $8.11 and a 50-day moving average of $7.09 [5] - The Relative Strength Index (RSI) is at 71.24, suggesting the stock is in a strong upward trend [5]